How to Optimize Cholesterol Management in High-Risk CV Patients

Agenda

AHA/ACC Guidelines on the Management of Blood Cholesterol

AHA/ACC Guideline: Lifestyle Modification for ASCVD Risk Reduction

Secondary Prevention in Patients Not at High ASCVD Risk

Secondary Prevention in Patients at Very High ASCVD Risk

FOURIER: Cumulative Incidence of CV Events

AHA/ACC Guidelines Primary Prevention of ASCVD

Cost-Effectiveness of PCSK9 Inhibitors

EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

Stepwise, Incremental Therapeutic Strategy for Lipid Reduction in High-Risk Patients

Second STEMI and Residual Risk

Myocardial Infarction and Life Expectancy by Sex and Ethnicity

7-Year Risk of a Second MI Among 30-Day Survivors of First MI

Patient Case

Controlling Modifiable Risk Factors Is Essential in High-Risk ACS Patients

Addressing Residual Risk: Every MI Patient Should Be On a Statin (and Possibly Ezetimibe As Well)

FOURIER: Cumulative Incidence of Cardiovascular Events

Fourier: Results of an Exploratory Analysis in Patients with LDL-C <0.26 mM at Week 4

Safety Data From 5 Alirocumab Trials: No Safety Signal for Very Low LDL-C Levels

AHA Guidelines for Secondary ASCVD Prevention: Use of PCSK9 Inhibitors

Case Study in Secondary Prevention in a Patient With PAD, CAD, or Polyarterial Disease

Case Presentation: Patient Characteristics

How Should Therapy Be Advanced for This Patient?

Presence of Residual CV Risk in Large Prospective Studies of Optimal Statin Therapy

The TIMI Risk Score for Secondary Prevention

What Types of Events Is This Patient at Risk For?

How Should the Patient With Multiple Risk Factors Be Managed?

FOURIER: Cumulative Incidence of CV Events

Older Patients and Optimal LDL-C Reduction Therapy

Are There LDL-C Levels That Are Too Low?

Summary

Real Life Data With PCSK9 Inhibitors

Introduction/Overview

Majority of Very High-Risk Patients Not at LDL-C Level Target, < 70 mg/dL

EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

LDL-C Reduction With PCSK9 Inhibitors: Real-World Data From a Regional Lipid Clinic

LDL-C Reduction From Baseline With PCSK9 Inhibitors at Various Doses

Observational Cohort Study: CV History at Baseline (N = 1186)

Median (Q1, Q3) LDL-C Reduction Following Evolocumab Initiation

Adverse Drug Reactions: Observational Cohort Study

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)